Blog

Photo from Yüksel Ürün/X

May 31, 2024, 10:51

Yüksel Ürün on CheckMate 901 trial

Yüksel Ürün shared a post on X:

“CheckMate 901 trial: Abstract #4509

For lymph node-only mUC, NIVO+GC resulted in durable disease control and significant OS and PFS improvements. Proud to have played a role in this impactful study.”

Yüksel Ürün

Source: Yüksel Ürün/X

Yüksel Ürün is a Medical Oncology professor at Ankara University School of Medicine in Turkey. His research focuses on genitourinary cancers, covering epidemiology, diagnosis, biomarkers, meta-analysis, and treatment outcomes. His dedication to patient care and research inspires positive change in the medical field.

Ankara University ASCO ASCO 2024 ASCO24 cancer CheckMate 901 clinical trial disease control durable treatment immunotherapy impactful study lymph node-only mUC metastatic urothelial carcinoma NIVO+GC OncoDaily Oncology OS improvements PFS improvements survival outcomes Yüksel Ürün

Mark Ruffalo and Brain Cancer: How He Went Against, How He Survived, and More

Sharon Osbourne and Colon Cancer: How She Went Against, How She Survived, and More

Marcia Cross and Anal Cancer: How She Went Against, How She Survived, and More

Pancreatic Cancer: Symptoms, Causes, Types, Diagnosis & Treatment

FDA approves Methotrexate for Pediatric acute Lymphoblastic Leukemia

Special Coverage